admin – Page 4909 – Get News Story

Surgical Sutures Market to Generate CAGR of 6.50% by 2031, Owing to Rise in Demand for Surgeries

“SkyQuest Technology”

Surgical Suture Market Size, Share, Growth Analysis, By Product (Suture Threads, Automated Suturing Devices), By Type (Multifilament Sutures, Monofilament Sutures), By Application (Cardiovascular Surgery, General Surgery), By End User (Hospitals, Ambulatory Surgical Centers), By Region – Industry Forecast 2024-2031

Surgical Sutures Market size was valued at USD 3.5 billion in 2022 and is poised to grow from USD 3.73 billion in 2023 to USD 6.17 billion by 2031, growing at a CAGR of 6.50% during the forecast period (2024-2031).

Several significant factors are expected to promote the growth of the global surgical sutures market. These include an aging population that is putting additional stresses on healthcare systems, rising chronic diseases requiring surgery, advancements in sutures used and their application procedures, and a focus on less invasive procedures. For instance, as projected in the ISAPS Global Survey 2022, plastic surgeons would perform around 14.9 million surgical and 18.8 million nonsurgical interventions globally in 2022 and a total overall increase of 11.2% in operations. Moreover, an increasingly prevalent lifestyles disease due to sedentary lifestyles is contributing to the increasing need for surgical sutures. Increasing rates of lifestyle diseases, including cancer, mental illness, ischemic heart disease, and cerebrovascular diseases among others, in the globe are driving up the demand for surgical sutures.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/surgical-suture-market

Absorbable Sutures Driving Change in Postoperative Care

Absorbable sutures are becoming popular due to their ability to reduce problems such as wound dehiscence and infection. They result in slow body dissolution, thus reducing the need for a follow-up treatment to extract them, which might seem uncomfortable to patients and slow speed of recovery. With increasing knowledge of the benefits absorbable sutures have in reducing postoperative complications and improving outcome, demand will steeply escalate over the next few years. This trend fits into a larger wave of surgical treatments that are patient-friendly and effective.

For instance, Ethicon, Inc., subsidiary of Johnson & Johnson, in February 2021 announced a new product launch by them, namely, V-LocTM PBT Absorbable Suture, which promises to bring about high strength as well as secure closure of wounds during various types of surgical operations.

Evolving Competitive Arena of Surgical Sutures

The surgical suture market is highly fragmented, and hundreds of companies operating in the market have created it. Though major companies dominate the market, an extensive sectoral presence in it is supported by many other small players. Regarding competitor rivalry, the competition in the surgical suture market is based on product quality, innovation, pricing, distribution channels, and level of customer service. This affects, among many other things, the market, and this spending on healthcare, the prevalence of chronic diseases, and the aging population. The companies operating in this market are spending more money on R&D to produce new innovative products to increase their share in the market.

For a tailored report, contact us to request a free customization:

https://www.skyquestt.com/speak-with-analyst/surgical-suture-market

How Major Players Are Shaping the Future of Surgical Sutures

Recent trends among the market leaders in the surgical sutures market point towards an innovative growth dynamic phase. Market majors still focus on better quality through improvement in product lines, expansion of portfolios with better features through advanced technologies in sutures and improvement in their networks to increase competition levels. Such a focus is driven by increasing healthcare needs, technological advancements and changing patient expectations. The market is experiencing tremendous transitions in terms of upgradation of surgical outcomes and operational efficiency due to the entry of major players into R&D.

Key Innovations by Market Players

In May 2021, Medtronic plc. closed its acquisition of privately held interventional medicine company Medicrea International SAS. On that account, the Company would enlarge the portfolio of surgical technologies, for example, with the sutures.
In March 2021, B. Braun Melsungen AG launched a new Monomax sutures product line on the European market. The fact that Monomax is a synthetic absorbable suture with high tensile strength and assured knot security reinforces its significant position in the market.
In February 2021, V-LocTM PBT Absorbable Suture was first introduced from its parent company, Johnson & Johnson, to the market by Ethicon, Inc. for surgical wound closures with very high strength and security.

Purchase now to gain valuable insights and stay informed:

https://www.skyquestt.com/buy-now/surgical-suture-market

This report covers the following segment:

A. Product

Absorbable Sutures
Non-Absorbable Sutures

B. Application

Cardiovascular Surgery
General Surgery
Gynecological Surgery
Orthopedic Surgery

C. Filament

Monofilament
Multifilament

D. End User

Hospitals
ASC
Clinic

This report covers following players:

3M Healthcare
Conmed Corporation
Sutures India
Teleflex Medical
Dolphin Sutures
Smith & Nephew
Medtronic
Johnson & Johnson
Peters Surgical
Mellon Medical B.V.
Aspide Medical
EndoEvolution, LLC
Boston Scientific Corporation
B.Braun Melsungen AG
Internacional Farmaceutica

The Global Surgical Sutures Market experiences a growth rate never witnessed before globally during the forecast period. Major growth stimulators for the market include growing incidence of chronic diseases, rise in surgical procedures, and increase in the adoption of advanced medical technology. Rising demand for minimally invasive surgeries will positively impact market growth.

To read the full report, please visit: https://www.skyquestt.com/report/surgical-suture-market

Related Report:

Surgical Devices Market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/surgical-suture-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surgical Sutures Market to Generate CAGR of 6.50% by 2031, Owing to Rise in Demand for Surgeries

Generator Market Size to Grow $32.98 billion by 2030 at a CAGR of 5.4% during the forecast period 2024 to 2030

“Browse 455 market data Tables and 78 Figures spread through 370 Pages and in-depth TOC on “Generator Market – Global Forecast to 2030″”

The Generator market was valued at USD 24.11 billion in 2024 and is estimated to reach USD 32.98 billion by 2030, registering a CAGR of 5.4% during the forecast period (2024–2030).

According to a research report “Generator Market by Fuel Type (Diesel, Gas, LPG, Biofuels), Power Rating (Up to 50 kW 51–280 kW, 281-500 kW, 501-2000 kW, 2001-3500 kW, Above 3500 kW), Application, End-User Industry, Design, Sales Channel, Region – Global Forecast to 2030″ , is forecast to reach USD 32.98 billion by 2030 from an estimated USD 24.11 billion in 2024, at a CAGR of 5.4% during the forecast period (2024-2030).

The main driver of the generator market is the increasing demand for a steady power supply across the healthcare, telecommunication, and IT sectors. The rise in frequent power cuts, frail grid infrastructure, and increased urbanization have seen a growing demand for generators as a source of backup power. Scorching industrialization and massive infrastructure development, such as new buildings, roads, and airports, accelerate generator sales. Renewable energy and hybrid generators are also becoming increasingly popular as cleaner and more efficient solutions.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47544335

Stand By segment by Application, is expected to be the fastest Generator market during the forecast period.

Stand By application is expected to account largest market share during the forecast period. The demand is seen especially concerning the reliable supply of backup power in critical industries, such as healthcare and data centers, and also on the commercial side. Ever-registered power supply downturns coupled with increasing demand for continuous electricity both in the developed and the emerging markets have been leading to this growth, as businesses prioritize reducing downtime and ensuring continuous operation.

Commercial segment by end-user, is expected to be the fastest Generator market during forecast period

The commercial part of end users is growing fast for several reasons: growing digitization of various industries, rising pressure on efficiency and cost-effectiveness, and subscription-based emerging models. Businesses continue investing in software and services that augment productivity and customer engagement. Moreover, the recent trend of data-driven decision-making goes hand in hand with targeted marketing strategies, which allows firms to better shape their offerings and strengthen loyalty among customers.

Asia Pacific is expected to be the fastest region in the Generator market during the forecast period

The major end users such as residential, commercial and industrial sectors (utilities/power generation, oil & gas, chemical & petrochemical, mining & metal, manufacturing, marine, construction and others) are expected to drive the generator market in Asia Pacific. The region is experiencing rapid development fueled by the growth of major economies such as China, India, South Korea, Japan, Indonesia, and Australia. Asia Pacific has emerged as a global hub for manufacturing activities, with virtually every industry experiencing growth.

Make an Inquiry @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=47544335

Key Market Players

The report profiles key players such Caterpillar (US), Cummins Inc. (US), Rolls-Royce Holdings (UK), Generac (US), Mitsubishi Heavy Industries (Japan), MAN Energy Solutions (Germany) and Briggs & Stratton (US).

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ’GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103,

Delray Beach, FL 33445

USA : 1-888-600-6441

newsletter@marketsandmarkets.com

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/generator-sales-market-47544335.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Generator Market Size to Grow $32.98 billion by 2030 at a CAGR of 5.4% during the forecast period 2024 to 2030

Lucintel Forecasts Medical Device Market to Reach $519.0 billion by 2030

“According to the recent study the medical device market is projected to reach an estimated $519.0 billion by 2030 from $374.0 billion in 2023, at a CAGR of 5.0% from 2024 to 2030. Growth in this market is primarily driven by critical role in the diagnosis, treatment, and monitoring of various medical conditions, enabling healthcare professionals to improve patient outcomes and enhance the quality of care”

According to the recent study the medical device market is projected to reach an estimated $519.0 billion by 2030 from $374.0 billion in 2023, at a CAGR of 5.0% from 2024 to 2030. Growth in this market is primarily driven by critical role in the diagnosis, treatment, and monitoring of various medical conditions, enabling healthcare professionals to improve patient outcomes and enhance the quality of care

Browse 73 figures / charts and 52 tables in this 202 -page report to understand trends, opportunities and forecast in medical device market by application (surgical and infection control devices, general medical devices, cardiovascular devices, orthopedic devices, home healthcare devices, and other devices), by function (diagnostic and monitoring, therapeutic, surgical and other devices), by end use (homecare medical device and hospital and ambulatory care medical device), and by region (North America, Europe, Asia Pacific, and the Rest of the World).

Lucintel forecasts that cardiovascular device will remain the largest segment over the forecast period due to increasing global geriatric population, inactive lifestyle, and poor eating habits.

Within the global medical device market, diagnostic and monitoring, therapeutic, and surgical are the major function segments. Surgical device will remain the largest segment over the forecast period due to increasing number of surgical procedures, growing aging population, and increase in incidence of several chronic diseases.

Download sample by clicking on medical device market

North America will remain the largest region during the forecast period mainly due to a large target patient pool coupled with a high adoption rates for advanced treatments in this region. Asia Pacific is expected to witness the highest growth over the forecast period due to growing health awareness, increasing per capita income, and improving healthcare infrastructure.

Medtronic, Johnson & Johnson, GE Healthcare, Siemens, and Cardinal Health are the major suppliers in the medical device market.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com To get access of more than 1000 reports at fraction of cost visit Lucintel’s Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1-972-636-5056

Explore Our Latest Publications

Truck Substation Market

Twintube Gas Pressure Shock Absorber Market

Underhood Work Light Market

Urban Microgrid System Market

Brazilian Composites Market

Invar Tooling Market

Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lucintel Forecasts Medical Device Market to Reach $519.0 billion by 2030

Chronic Plaque Psoriasis Market Size is expected to grow at a CAGR of 2.8% during the forecast period (2024-2034), estimates DelveInsight

DelveInsight’s “Chronic Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Plaque Psoriasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Plaque Psoriasis Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Plaque Psoriasis prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Plaque Psoriasis Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Chronic Plaque Psoriasis Market with DelveInsight’s In-Depth Report @ Chronic Plaque Psoriasis Market Size

Key Takeaways from the Chronic Plaque Psoriasis Market Report

In November 2024:- Zai Lab (Hong Kong), Ltd- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis.
In the 7MM, the US accounted for the highest prevalent cases of chronic plaque psoriasis in 2023, with around 6,425,000 cases; these numbers are expected to increase during the forecast period.
In 2023, nearly 80% cases of chronic plaque psoriasis belonged to mild category.
The leading Chronic Plaque Psoriasis Companies such as Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others
Promising Chronic Plaque Psoriasis Therapies such as RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others.

Stay ahead in the Chronic Plaque Psoriasis Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Plaque Psoriasis Market Outlook

Chronic Plaque Psoriasis Epidemiology Segmentation

The chronic plaque psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Prevalent Cases of Plaque Psoriasis, Total Prevalent Cases of Chronic Plaque Psoriasis, Gender-Specific Prevalent cases of Chronic Plaque Psoriasis, Age-Specific Cases of Chronic Plaque Psoriasis, Severity Specific Cases of Chronic Plaque Psoriasis, and Total Treated Cases of Chronic Plaque Psoriasis

Download the report to understand which factors are driving Chronic Plaque Psoriasis epidemiology trends @ Chronic Plaque Psoriasis Prevalence

Chronic Plaque Psoriasis Marketed Drugs

TALTZ (ixekizumab): Eli Lilly and Company

It is a humanized IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. TALTZ inhibits the release of pro-inflammatory cytokines and chemokines. The US FDA approved TALTZ (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasisin adult patients who are candidates for systemic therapy or phototherapy.

SILIQ (brodalumab): AstraZeneca/Bausch Health

The US FDA approved SILIQ injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq is an IL-17 receptor monoclonal antibody for patients with moderate-to-severe plaque psoriasis, a chronic, debilitating skin disease that causes red patches of skin covered with silvery scales.

Chronic Plaque Psoriasis Emerging Drugs

TAK-279: Takeda

In September 2023, Takeda announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase IIb trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.

Currently, a Phase III trial is being carried out in patients with Plaque Psoriasis to demonstrate how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.

ME3183: Meiji Seika Pharma

ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji. In August 2023, Meiji Seika Pharma announced positive results in the Phase II study of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada.

SGX302: Soligenix

SGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. In January 2024, Soligenix announced preliminary top-line results of its ongoing Phase IIa trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.

Get In-Depth Knowledge on Chronic Plaque Psoriasis Market Trends and Forecasts with DelveInsight @ Chronic Plaque Psoriasis Treatment Market

Chronic Plaque Psoriasis Market Outlook

Psoriasis, a chronic relapsing disease, often requires long-term therapy, with treatment choices influenced by disease severity, comorbidities, and healthcare access. Patients are generally categorized as having mild or moderate-to-severe psoriasis. Mild cases are typically treated with topical agents like glucocorticoids, vitamin D analogs, and phototherapy, while moderate-to-severe cases may require systemic treatments, including biologics. Biologics, such as TNF inhibitors (e.g., adalimumab) and interleukin-targeting therapies (e.g., ustekinumab, secukinumab), have emerged as potent options, particularly when traditional therapies fail or are unsuitable. Despite the availability of biosimilars, their uptake, especially for infliximab, has been slow in the US. Studies show that treatment rates for psoriasis hover around 50-60%, with oral therapies gaining traction in recent years. Patients often switch therapies, with adalimumab being a common choice across multiple lines of treatment.

Scope of the Chronic Plaque Psoriasis Market

Coverage- 7MM
Chronic Plaque Psoriasis Companies- Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others
Chronic Plaque Psoriasis Therapies- RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others.
Chronic Plaque Psoriasis Market Dynamics: Chronic Plaque Psoriasis Market Drivers and Barriers
Chronic Plaque Psoriasis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Plaque Psoriasis Market Report @ Chronic Plaque Psoriasis Market Drivers and Barriers

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary of Chronic Plaque Psoriasis

4 Key Events

5 Chronic Plaque Psoriasis Epidemiology and Market Forecast Methodology

6 Chronic Plaque Psoriasis Market Overview at a Glance

7 Disease Background and Overview: Chronic Plaque Psoriasis

8 Chronic Plaque Psoriasis Treatment and Management

8.1 Treatment Guidelines and Recommendations

9 Epidemiology and Patient Population of Chronic Plaque Psoriasis in the 7MM

10 Chronic Plaque Psoriasis Patient Journey

11 Key Endpoints in Chronic Plaque Psoriasis

12 Chronic Plaque Psoriasis Marketed Therapies

13 Chronic Plaque Psoriasis Emerging Therapies

14 Chronic Plaque Psoriasis: Seven Major Market Analysis

15 Chronic Plaque Psoriasis Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Plaque Psoriasis Market Size is expected to grow at a CAGR of 2.8% during the forecast period (2024-2034), estimates DelveInsight

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics

The Key Alport Syndrome Companies in the market include – Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others.

DelveInsight’s “Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast

Some of the key facts of the Alport Syndrome Market Report:

The Alport Syndrome market size was valued ~USD 20 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2024, ENYO Pharma announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.
The overall number of existing cases of Alport Syndrome across the seven major markets (7MM) was approximately 160,000 in 2023, with projections indicating a rise by 2034.
In the United States, there were nearly 68,000 existing cases of Alport Syndrome in 2023.
In 2023, gender-specific cases of Alport Syndrome in the US consisted of approximately 52% males and 48% females.
In 2023, among the type-specific cases, approximately 11,500 cases were attributed to XLAS, which constituted 85% of the cases in the US.
Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
In 2022, there were around 2,200 cases of Alport syndrome in the age group 2-11, nearly 1,900 cases in the age group 12-17, and almost 25,000 cases in the age group 18 and above across the 7 Major Markets (7MM).
The Alport Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alport Syndrome pipeline products will significantly revolutionize the Alport Syndrome market dynamics.

Alport Syndrome Overview

Alport Syndrome is a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities. It primarily affects the glomeruli, the tiny blood vessels in the kidneys that filter wastes and excess fluids from the blood to form urine. This condition typically results from mutations in genes that encode proteins involved in the structure and function of the glomeruli and the inner ear.

Get a Free sample for the Alport Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/alport-syndrome-market

Alport Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alport Syndrome Epidemiology Segmentation:

The Alport Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Alport Syndrome in the 7MM
Total Diagnosed Prevalent Cases of Alport Syndrome in the 7MM
Gender-specific Cases of Alport Syndrome in the 7MM
Age-specific Cases of Alport Syndrome in the 7MM
Type-specific Cases of Alport Syndrome in the 7MM

Download the report to understand which factors are driving Alport Syndrome epidemiology trends @ Alport Syndrome Epidemiology Forecast

Alport Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alport Syndrome market or expected to get launched during the study period. The analysis covers Alport Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alport Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alport Syndrome Therapies and Key Companies

ELX-02: Eloxx Pharmaceuticals, Inc.
Bardoxolone Methyl: Biogen
R3R01: River 3 Renal Corp.
Sparsentan: Travere Therapeutics, Inc.
Atrasentan: Chinook Therapeutics U.S., Inc.
Finerenone: Bayer

Discover more about therapies set to grab major Alport Syndrome market share @ Alport Syndrome Treatment Landscape

Alport Syndrome Market Strengths

With a deeper understanding of the genetic basis of Alport syndrome, personalized treatment strategies can be tailored to an individual’s specific genetic profiles. ELX-02 is expected to garner the first mover advantage in Alport syndrome apart from being the first gene therapy with reduced frequency of administration (8 weeks).
An increase in research and development has paved the way for discovering novel MoA therapies such as dual NOX inhibitor (setanaxib), semaphorin-3A blocker (BAY3401016), selective endothelin A receptor antagonist (atrasentan) amidst the usage of ACE/ARB inhibitors as standard of care.

Alport Syndrome Market Opportunities

Genetic advances may open the way for personalized treatment tailored to the particular genetic profiles of individuals with Alport syndrome. Thus, there is a huge opportunity for precision medicine approaches.
Patient advocacy groups such as the Alport Syndrome Foundation can play a pivotal role in shaping the landscape for Alport syndrome. This foundation directs the majority of its resources to research and research-related activities resulting in groundbreaking knowledge and clinical trials pertaining to Alport syndrome.

Scope of the Alport Syndrome Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Alport Syndrome Companies: Eloxx Pharmaceuticals, Inc., Biogen, River 3 Renal Corp., Travere Therapeutics, Inc. , Chinook Therapeutics U.S., Inc., Bayer, and others
Key Alport Syndrome Therapies: ELX-02, Bardoxolone Methyl, R3R01, Sparsentan, Atrasentan, Finerenone, and others
Alport Syndrome Therapeutic Assessment: Alport Syndrome current marketed and Alport Syndrome emerging therapies
Alport Syndrome Market Dynamics: Alport Syndrome market drivers and Alport Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Alport Syndrome Unmet Needs, KOL’s views, Analyst’s views, Alport Syndrome Market Access and Reimbursement

To know more about Alport Syndrome companies working in the treatment market, visit @ Alport Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Alport Syndrome Market Report Introduction

2. Executive Summary for Alport Syndrome

3. SWOT analysis of Alport Syndrome

4. Alport Syndrome Patient Share (%) Overview at a Glance

5. Alport Syndrome Market Overview at a Glance

6. Alport Syndrome Disease Background and Overview

7. Alport Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Alport Syndrome

9. Alport Syndrome Current Treatment and Medical Practices

10. Alport Syndrome Unmet Needs

11. Alport Syndrome Emerging Therapies

12. Alport Syndrome Market Outlook

13. Country-Wise Alport Syndrome Market Analysis (2020–2034)

14. Alport Syndrome Market Access and Reimbursement of Therapies

15. Alport Syndrome Market Drivers

16. Alport Syndrome Market Barriers

17. Alport Syndrome Appendix

18. Alport Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics

Cyanoacrylate Adhesives Market with Business Outlook, Competitive Analysis, Market Growth, Sales, Trends, Service, Forecast

“Browse 236 market data Tables and 64 Figures spread through 282 Pages and in-depth TOC on “Cyanoacrylate Adhesives Market”

The Cyanoacrylate Adhesives market is witnessing rapid growth driven by demand in electronics, medical, and automotive sectors. Known for fast curing and strong bonding, cyanoacrylate adhesives are essential for precision applications, supporting advancements in modern manufacturing.

The cyanoacrylate adhesives (CA) market is projected to grow from USD 2.22 billion in 2024 to USD 2.56 billion by 2029, at a CAGR of 2.9% between 2024 and 2029. This report provides an in-depth evaluation of the industry, focusing on cyanoacrylate adhesives (CA) market size, trends, drivers, challenges, competitive landscape, and future growth potential. Cyanoacrylate adhesives play a vital role in various industries, driving market growth through their diverse applications. The use of cyanoacrylate adhesives in industrial, woodworking, transportation, and medical applications has improve the performance of products with its remarkable characteristics, such as, strong bonding, rapid curing, and high shear strength. Cyanoacrylate adhesives provide cost saving and quick adhesion solutions for diverse industries including automotive, aerospace, medical and others to address the challenges in bonding and repair applications. Cyanoacrylate adhesives include ethyl cyanoacrylate, methyl cyanoacrylate, butyl cyanoacrylate and allyl cyanoacrylates.

In addition, the exceptional properties of cyanoacrylate adhesives drives the market demand in medical devices and surgical applications. These adhesives are extensively used in surgical procedures and in assembly processes of medical equipements. Cyanoacrylate adhesive market expansion in medical sector is being driven by the growing demand of rapid curing time and strong fast-bonding adhesives.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158562220

Cyanoacrylate Adhesives Market Key Players

The major players operating in this business are Henkel AG & Co. KGaA (Germany), 3M (US), Sika AG (Switzerland), Huntsman International LLC (US), Arkema (France), Toagosei Co., Ltd (Japan), Illinois Tool Works Inc. (US), and Pidilite Industries Limited (India).

Henkel AG & Co. KGaA: Henkel AG & Co. KGaA, a parent company of Henkel Group, is a leading market player in both industrial and consumer sectors, supported by its strong brands and pioneering technologies, including Persil, Schwarzkopf, and Loctite. The company was established in 1876 with a headquarter in Düsseldorf, Germany.

Henkel AG & Co. KGaA has strong product portfolio that includes renowned hair care products, laundry detergents, fabric softeners, as well as adhesives, sealants, and functional coatings. The company operates globally under two primary business segments: Adhesive Technologies and Consumer Brands. The adhesive technologies business segment of the company is a global leader in adhesives including cyanoacrylates, sealants, and functional coatings, catering both industrial clients and consumers.

The company has wide global presence with a 161 manufacturing sites in 55 countries worldwide. The largest production facilities of the company are situated in Bowling Green, Kentucky, USA, and in Düsseldorf, Germany.

In February 2024, the company has launched two new advanced products of cyanoacrylate adhesives developed for medical device applications to enhance safety and performance. These medical grade products namely Loctite 4011S and Loctite 4061S offer strong bonding on plastics, rubber, and metals.

Get Sample Copy of this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158562220

H.B. Fuller Company: H.B. Fuller Company, established in 1887, is a global leader in the formulation, manufacturing, and marketing of adhesives and specialty chemical products. The company conducts its operations in three reportable segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. The company primarily offers wide range of cyanoacrylate adhesives to enhance the performance of various consumer and industrial goods, including food and beverage containers, medical products, automotive components, and electronics. It also provides sealing and waterproofing solutions for infrastructure, pressure-sensitive adhesives for roofing, and grouts and mortars for flooring applications to meet the market demand.

With a headquarter in Minnesota, US, H.B. Fuller Company has built strong global presence with operation facilities in 35 countries across North America, Europe, Latin America, Asia Pacific, India, the Middle East & Africa.

In May 2024, the company has acquired a US based ND Industries Inc., a provider of specialty adhesives and fastener locking and sealing solutions. H.B. Fuller Company has took over the Vibra-Tite products of ND Industries Inc. into its existing portfolio, which includes epoxy, cyanoacrylate, UV curable, and anaerobic adhesives. The main objective of this acquisition is to expand the product offering and market reach of the company within the functional coatings, adhesives, sealants, and elastomers sector.

Ethyl cyanoacrylate by chemistry segment dominate the market by highest share of the cyanoacrylate adhesives market during the forecasted period.

Ethyl cyanoacrylates are dominating because of their balanced mechanical qualities andextensive availability. Because of its rapid curing time, excellent bonding capabilities, and versatility, it can be adhere on range of substrates, including plastics, metals, and ceramics. Additionally, continuous advancements in adhesive technology have improved the formulation of ethyl cyanoacrylate, enhancing properties such as environmental resistance and curing speed.

With ongoing technological advancements and innovations in cyanoacrylate adhesives, coupled with expanding applications in emerging industries, the segment is expected to experience robust growth in the forecast period.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=158562220

Asia Pacific region is likely to be the fastest growing cyanoacrylate adhesives market during the forecast period.

Rapid industrialization and urbanization in the Asia Pacific region are driving demand across various sectors including industrial, automotive, electronics, and medical industry. With expanding manufacturing bases in countries like China, Japan, and India there’s a rising need for cyanoacrylate adhesives for various applications. Moreover, ongoing advancement in manufacturing technologies and materials, particularly in China and Japan, are boosting demand in diverse industrial sectors for strong and rapid curable adhesive solutions. Advancements in cyanoacrylate adhesives tailored to wide range of industrial application needs are poised to further stimulate market growth in the region.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cyanoacrylate Adhesives Market with Business Outlook, Competitive Analysis, Market Growth, Sales, Trends, Service, Forecast

Lucintel Forecasts Micro LED Market to Reach $54.5 billion by 2030

“According to the recent study the Micro LED Market is projected to reach an estimated $54.5 billion by 2030 from $1.5 billion in 2023, at a CAGR of 66.4% from 2024 to 2030. Growth in this market is primarily driven by growth in smartphones and wearable devices and increasing demand for brighter and better display solutions.”

According to the recent study the Micro LED Market is projected to reach an estimated $54.5 billion by 2030 from $1.5 billion in 2023, at a CAGR of 66.4% from 2024 to 2030. Growth in this market is primarily driven by growth in smartphones and wearable devices and increasing demand for brighter and better display solutions.

Browse 87 figures / charts and 87 tables in this 183 -page report to understand trends, opportunities and forecast in micro LED market by end use industry (consumer electronics, automotive, advertisement, aerospace & defense, and others), Panel Size (micro-displays, small-sized & medium-sized, and large panels), Application (display and lighting) by region (North America, Europe, Asia Pacific, and the Rest of the World).

Lucintel forecasts that display will remain the largest application and it is also expected to witness the highest growth over the forecast period as increasing demand for better display solutions.

Large panel will remain the largest segment by panel size and micro display segment is also expected to witness the highest growth over the forecast period due to increasing demand for smart phone and wearables devices.

Download sample by clicking on Micro LED Market

Asia Pacific will remain the largest region due to increasing investment by electronics giants in global micro led market. APAC is expected to witness the highest growth over the forecast period supported by increasing demand for consumer electronics devices such as smartwatches, smart devices, and AR/VR devices, smartphones, televisions, and laptops.

Apple Inc, Samsung Electronics, Sony Corporation, Epistar Corporation, Lumens, Plessy Semiconductor, X-Celeprint, PlayNitride, VerLASE Technologies LLC, Plessey Semiconductor Ltd., JBD Inc., Ostendo Technologies, Inc., MICLEDI, Microluce are the major suppliers in the micro LED market.

About Lucintel

Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1 972 636 5056

Explore Our Latest Publications

Bioleaching Market in Canada

Circular Oxygen Chamber Market in Canada

Civil Helicopter Market in Canada

Cold Heading Machine Market in Canada

Copper, Nickel, Lead And Zinc Market in Canada

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lucintel Forecasts Micro LED Market to Reach $54.5 billion by 2030

Market Alert: Beyond Oil (CSE: BOIL) Accelerates Global Expansion with Key first Order in Asian Market

TL;DR: Beyond Oil Ltd. has taken a significant step in its global expansion with its first Asian order from Philippine chain Hap Chan. This milestone follows a successful pilot, integrating Beyond Oil’s filtration powder across 100+ locations. The order highlights Beyond Oil’s innovative tech for healthier, sustainable frying, aligning with its strategy to expand in high-demand markets like Asia and North America.

Beyond Oil (CSE: BOIL) (OTCQB: BEOLF) has taken a significant step forward in its global growth strategy by securing its first direct sale in Asia. This milestone order from Hap Chan, a prominent Philippine chain with 100+ restaurants, underscores Beyond Oil’s ongoing global expansion, especially in large, densely populated markets.

This order, which follows an extensive pilot program, will see Hap Chan integrate Beyond Oil’s powdered filtration technology across its 100+ locations in the Philippines. The initial purchase includes over 10,000 units of Beyond Oil’s filtration powder, a product engineered to extend frying oil lifespan, reduce waste, lower costs, and enhance the health profile of fried food. Beyond Oil’s technology is aimed at addressing rising consumer and market demands for sustainability and efficiency in food service.

Beyond Oil CEO Jonathan Or emphasized the importance of entering Asia, one of the largest markets for fried food, as a critical component of Beyond Oil’s strategy to accelerate growth. This entry also signals a commitment to further expand across Asia, with pilot successes like Hap Chan’s adoption positioning Beyond Oil to build relationships with additional high-volume chains.

This development aligns with Beyond Oil’s broader growth trajectory. Asia’s densely populated and sustainability-conscious market presents a strategic opportunity for Beyond Oil’s filtration powder, which addresses consumer preferences for healthier fried food by targeting and reducing harmful compounds like free fatty acids and acrylamide. Beyond Oil’s product aligns with a global shift toward health-focused, sustainable practices in food production, which is particularly resonant in high-demand regions.

Beyond Oil’s technology holds notable regulatory and scientific backing, with validations from the FDA, Health Canada, and Israel’s Ministry of Health. Research from the Hebrew University of Jerusalem, led by Professor Nissim Garti, further supports the product’s health benefits, underscoring Beyond Oil’s credibility and appeal in markets worldwide.

Beyond Oil’s momentum isn’t limited to Asia. The company has expanded its distribution network in North America via a strategic agreement with West Coast Reduction Ltd. (WCRL), which serves as its exclusive distributor in Canada for both the food-service and industrial frying sectors. Since spring 2024, this partnership has helped Beyond Oil demonstrate and secure agreements with restaurant groups across Western Canada, laying the foundation for broader market adoption.

The recent order from Hap Chan is the latest in a series of strategic moves, positioning Beyond Oil as a leading force in sustainable food tech on a global scale. While currently focused on food service, Beyond Oil’s filtration solutions also offer potential for industrial frying, a market valued at up to $700 billion globally, according to the company.

As Beyond Oil advances its global expansion strategy across key markets like Asia and North America, it seems that the company is working hard to deliver value to shareholders and the industry alike. This accelerated growth alongside the company’s innovative offering positions it to potentially lead a sustainable revolution for frying oil management, catering to the evolving demands for eco-friendly, health-conscious solutions in food tech.

Quick Links, Read More >>

> Beyond Oil Expands Sales into Eastern Europe with 16 Ton Order from Franchisee of Global Fast-Food Chain

> Beyond Oil and West Coast Reduction Provide Commercial Update to Strategic Partnership in North America

> Steakholder Foods is Paving the Way for Alternative Protein Commercialization with Recent Strategic Milestones

This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. The Author, Global Markets News Network, is a commercially operated digital brand compensated by the issuer (Beyond Oil) to provide coverage of its news and developments, among other things. Readers are encouraged to read the the full disclaimers and disclosures document that the article is subject to. This article may include forward looking statements which cannot be guaranteed as discussed in the documentation. https://justpaste.it/7796t/pdf

Media Contact
Company Name: Global Markets News Network
Contact Person: Market News Desk
Email: Send Email
Country: Canada
Website: https://www.futuremarketsresearch.com/global-markets-news

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Market Alert: Beyond Oil (CSE: BOIL) Accelerates Global Expansion with Key first Order in Asian Market

Market Alert: Steakholder Foods Advances in 3D-Printed Seafood with Grant Funding; Continues Commercialization Journey

TL;DR: Steakholder Foods Ltd. (NASDAQ: STKH) secures a second $270K grant from the Singapore-Israel Industrial R&D Foundation, totaling $490K of a $1M grant to advance its 3D-printed plant-based seafood, including fish and eel. Steakholder’s recent milestones signal its transition from from R&D to commercialization – the company has recently partnered with Wyler Farm and Bondor Foods, and opened a demonstration center.

Steakholder Foods Ltd. (NASDAQ: STKH), an innovator in alternative proteins and 3D food printing, has reached another milestone in its development of plant-based seafood alternatives, securing a second payment of $270,000 from a grant awarded by the Singapore-Israel Industrial R&D Foundation (SIIRD). This latest installment brings Steakholder Foods’ funding from SIIRD to $490,000 out of a total grant of $1 million, a financial boost aimed at supporting the company’s work in 3D-printed, plant-based fish and eel products. The project, backed by SIIRD’s resources, marks another step forward for Steakholder Foods as it continues its shift from R&D to revenue-generating commercialization.

This grant installment was triggered by Steakholder Foods’ progress in creating plant-based 3D-printed fish and eel, adding to a lineup of sustainable protein alternatives the company has pioneered. Steakholder’s ongoing efforts in developing unique premix formulations to replicate the texture and flavor of eel, in particular, reflect the company’s commitment to innovation in food technology. With a focus on products that appeal to consumer preferences for taste and texture, Steakholder’s developments are geared towards a growing market eager for more sustainable and plant-based options.

Strategic Partnerships Fuel Growth in the Alternative Protein Sector

Since its founding in 2019, Steakholder Foods has positioned itself as a leader in alternative proteins, utilizing cutting-edge 3D printing to replicate the textures and flavors of traditional meats and seafood. In early 2024, the company transitioned from R&D into commercialization, signing agreements with key partners to bring its proprietary technologies to market. These partnerships, including collaborations with Wyler Farm and Bondor Foods, aim to expand the availability of Steakholder’s plant-based alternatives across multiple regions.

In March, Steakholder Foods reached its first SIIRD milestone with the successful production of 3D-printed hybrid fish, leveraging its proprietary Printer HD144 and Drop Location in Space (DLS)™ printing technology. The company has also expanded its product lines with new fish and eel alternatives, achieving progress that earned this second SIIRD grant installment. The grant not only provides valuable funding but also reinforces Steakholder’s credibility within the alternative protein industry as it strives to meet growing global demand for plant-based foods.

Market Demand and Growing Consumer Interest

The alternative protein market is witnessing significant growth, driven by rising consumer awareness of health, sustainability, and ethical considerations. Analysts project that the sector, currently valued at $76.3 billion, could reach $423 billion by 2033 as consumer interest in plant-based and sustainable food options continues to rise. As Steakholder Foods builds out its seafood alternatives, the company is well-placed to capture market share among consumers seeking ethical, sustainable food sources without sacrificing taste or quality.

Steakholder Foods’ 3D printing capabilities have enabled it to craft realistic textures in plant-based products that resonate with consumers. By replicating traditional protein sources like beef, white fish, shrimp, and eel, Steakholder aligns itself with the shifting market dynamics that favor plant-based proteins over conventional meat. The recent launch of its demonstration center in Israel further underscores its commitment to driving consumer interest and showcases the production capabilities of its 3D printing technology.

Revenue Generation and Financial Milestones

A key element of Steakholder Foods’ strategy has been its focus on building revenuestreams through strategic partnerships. In 2024, the company received initial purchase orders from Wyler Farm for its SH™-Beef premix blend and Bondor Foods for proprietary plant-based premixes used in producing white fish and salmon patties. These purchase orders represent a shift toward recurring revenue and serve as proof of concept for Steakholder’s technology and products.

To bolster its commercial reach, Steakholder opened a state-of-the-art Demonstration Center in September 2024, where potential partners can view live demonstrations of its 3D printing technology. The center provides an immersive experience in plant-based meat production, including tasting sessions that showcase the quality of Steakholder’s alternatives. This hands-on approach has proven to be an effective tool for generating interest and expanding the company’s network of clients and partners.

Financially, Steakholder Foods has also implemented cost-saving measures, reducing its net losses by 53% year-over-year as of the first half of 2024. By securing non-dilutive funding sources like the SIIRD grant and managing operational costs, the company has positioned itself for a path toward potential profitability. CEO Arik Kaufman noted that while initial revenues are modest, they signal the early stages of a recurring revenue model that could drive long-term growth.

Looking Ahead: New Frontiers for Steakholder Foods

The $270,000 SIIRD installment is not only a financial boost but a recognition of Steakholder Foods’ advancements in 3D-printed plant-based seafood. The funding enables the company to continue refining its products and bringing new textures, flavors, and food formats to market. Steakholder is currently developing a 3D-printed eel prototype using innovative premixes, a product designed to meet specific consumer demands in texture and taste.

As the company progresses through its next phases of development and partnership building, it is also exploring potential high-impact agreements that could further expand its reach. In discussions for an international agreement set to close in early 2025, Steakholder Foods aims to leverage its advanced technology to scale production and broaden its market presence.

With the alternative protein and 3D food printing markets projected to experience exponential growth, Steakholder Foods appears well-equipped to be at the forefront of this transformation. The company’s journey from R&D to commercialization underscores its commitment to sustainability and technological innovation, setting a solid foundation for future growth. As demand for sustainable food options intensifies, Steakholder Foods could play a pivotal role in shaping the future of food production.

Read More >>

***

This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. The Author, Global Markets News Network, is a commercially operated digital brand compensated by the above mentioned company to provide coverage of its news and developments, among other things. Readers are encouraged to read the the full disclaimers and disclosures document that the article is subject to, detailing financial compensation and commercial relationships. This article may include forward looking statements which cannot be guaranteed as discussed in the documentation. https://justpaste.it/bdh8v/pdf

Media Contact
Company Name: Global Markets News Network
Contact Person: Editorial Desk
Email: Send Email
Country: United States
Website: https://www.futuremarketsresearch.com/global-markets-news

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Market Alert: Steakholder Foods Advances in 3D-Printed Seafood with Grant Funding; Continues Commercialization Journey

Chronic Obstructive Pulmonary Disease Market Size was valued at USD 16,075 million in 2023, estimated DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Obstructive Pulmonary Disease Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Obstructive Pulmonary Disease prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Obstructive Pulmonary Disease market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Chronic Obstructive Pulmonary Disease Market with DelveInsight’s In-Depth Report @ Chronic Obstructive Pulmonary Disease Market Size

Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report

In November 2024;- Merck Sharp & Dohme LLC- A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.
In November 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
In November 2024:- Sanofi- The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.
In November 2024:- AstraZeneca- A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE).
DelveInsight’s analyst estimate that approximately 44.2 million Diagnosed Prevalent Cases of COPD were found in 2023 in the 7MM.
The United States exhibited the highest diagnosed prevalent population of COPD, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of COPD in the US was around 18.3 million in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.
According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of COPD in EU4 and the UK were found to be ~18.6 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of COPD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.
The estimates show the Total Diagnosed Prevalent Cases of COPD in Japan was found to be around 7.2 million in 2023, which is estimated to increase by 2034 at a significant CAGR.
The Gender-specific Cases of COPD in the UK were ~1.7 million for females and ~2 million for males in 2023 and are expected to increase within the forecast period (2024–2034). The increased prevalence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.
According to the analysis performed by DelveInsight’s experts, the Age-specific Cases of COPD were categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years. The higher number of cases (~4.8 million) was accounted for by the 55-64 year age group in 2023 in the US.
The leading Chronic Obstructive Pulmonary Disease Companies such as Sanofi/Regeneron Pharmaceuticals, Verona Pharma PLC, Regeneron Pharmaceuticals, AstraZeneca, GlaxoSmithKline (), Mereo BioPharma, and others.
Promising Chronic Obstructive Pulmonary Disease Therapies such as Itepekimab, Ensifentrine, Dupilumab, Acumapimod, Benralizumab, Mepolizumab, and others.

Stay ahead in the Chronic Obstructive Pulmonary Disease Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease Epidemiology

Total Diagnosed Prevalent Cases
Subtype-specific Diagnosed Prevalent Cases
Gender-specific Diagnosed Prevalent Cases
Age-specific Diagnosed Prevalent Cases
Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation,
Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Prevalence

Chronic Obstructive Pulmonary Disease Marketed Drugs

Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca

Approved in April 2019, Duaklir (aclidinium bromide/formoterol fumarate 400 µg/12 µg twice-daily) is a fixed-dose LAMA/LABA combination of two long-acting bronchodilators – aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). Duaklir Pressair contains two bronchodilators: aclidinium, a long-acting muscarinic antagonist (also known as an anticholinergic), and formoterol, a long-acting beta-2-adrenergic agonist.

DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting the alpha chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged =12 with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. The drug is currently in Phase III of clinical development for COPD.

In September 2024, the US FDA approved DUPIXENT (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for COPD.

In January 2023, itepekimab received FTD from the US FDA for the treatment of COPD.

FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab), currently in Phase III, is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. Besides, it is an afucosylated IgG which gives it a high affinity for the Fc?RIIIa receptor in natural killer cells, macrophages, and neutrophils.

Get In-Depth Knowledge on Chronic Obstructive Pulmonary Disease Market Trends and Forecasts with DelveInsight @ Chronic Obstructive Pulmonary Disease Treatment Market

Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. Abnormalities in the lungs’ small airways lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be the destruction of parts of the lung, mucus blocking the airways, inflammation, and swelling of the airway lining. COPD and asthma share common symptoms (coughing, wheezing, and difficulty breathing), and people may have both conditions.

Scope of the Chronic Obstructive Pulmonary Disease Market Report

Coverage- 7MM
Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
Chronic Obstructive Pulmonary Disease Market Dynamics: Attribute Analysis of Emerging Chronic Obstructive Pulmonary Disease Drugs
Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Obstructive Pulmonary Disease Market Report @ Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance

4. Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)

10. Marketed Therapies

11. Emerging Drugs

12. Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Disease Market Size was valued at USD 16,075 million in 2023, estimated DelveInsight